Physician profile
Myra Woolery
NPI 1588259782
$2,141.91
in general payments reported to CMS, 2019-2025
16 companies · $759 in 2025
The $759 reported for 2025 was more than what 99% of Pediatrics (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $90.40).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $293 · 2023: $530 · 2024: $226 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $315.46 | 2021-2025 | |
| Btg International INC. | $237.39 | 2023 | |
| Servier Pharmaceuticals LLC | $237.35 | 2023-2025 | |
| Genzyme Corporation | $138.60 | 2025 | |
| G1 Therapeutics, INC. | $126.00 | 2022 | |
| Celgene Corporation | $124.99 | 2021 | |
| Kite Pharma, INC. | $121.84 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $118.20 | 2021 | |
| Genmab U.S., INC. | $113.40 | 2024 | Epkinly |
| Jazz Pharmaceuticals INC. | $112.59 | 2024 | |
| Foundation Medicine, INC. | $109.31 | 2023 | Foundationone Cdx |
| Pfizer INC. | $91.61 | 2025 | |
| Janssen Biotech, INC. | $89.45 | 2025 | Rybrevant, Carvykti |
| Exelixis INC. | $84.40 | 2025 | Cabometyx |
| Fennec Pharmaceuticals, INC. | $63.94 | 2023 | Pedmark |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Y-Mabs Therapeutics, INC. | $57.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Woolery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.